Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
amphetamine
Hallucinogen |
| gptkbp:belongs_to_class |
gptkb:2C_family
|
| gptkbp:CASNumber |
342434-22-2
|
| gptkbp:chemicalFormula |
C10H14ClNO2
|
| gptkbp:discoveredBy |
gptkb:Alexander_Shulgin
|
| gptkbp:duration_of_effects |
4–8 hours
|
| gptkbp:effect |
euphoria
hallucinations altered perception visual enhancement |
| gptkbp:firstSynthesized |
1983
|
| gptkbp:hasSMILES |
COC1=CC(=C(C=C1CCN)OC)Cl
|
| gptkbp:hasStreet |
Chlorophen
|
| https://www.w3.org/2000/01/rdf-schema#label |
2C-C
|
| gptkbp:IUPACName |
2-(4-chloro-2,5-dimethoxyphenyl)ethan-1-amine
|
| gptkbp:legal_status_in_Canada |
Schedule III controlled substance
|
| gptkbp:legal_status_in_United_Kingdom |
Class A drug
|
| gptkbp:legal_status_in_United_States |
Schedule I controlled substance
|
| gptkbp:meltingPoint |
208–210 °C
|
| gptkbp:mentions |
gptkb:PiHKAL
|
| gptkbp:molecularWeight |
215.68 g/mol
|
| gptkbp:PubChem_CID |
60808
|
| gptkbp:relatedTo |
gptkb:2C-B
gptkb:2C-I |
| gptkbp:routeOfAdministration |
oral
insufflation |
| gptkbp:bfsParent |
gptkb:NBOMe_series
gptkb:2C_family |
| gptkbp:bfsLayer |
7
|